- ICH GCP
- Registro de ensayos clínicos de la UE
Últimos ensayos
EudraCT Number: 2016-002324-92 | Sponsor Protocol Number: P150904 | Start Date: | |||||||||||
Sponsor Name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Efficiency of Levamisole for Maintaining Remission After the First Flare of Steroid Sensitive Nephrotic Syndrome in Children (NEPHROVIR3) | |||||||||||||
Medical condition: Sensitive nephrotic syndrome in children | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000195-13 | Sponsor Protocol Number: V59P5 | Start Date: | ||||||
Sponsor Name: Novartis Vaccines and Diagnostics | ||||||||
Full Title: A Phase II, Randomized, Open label, Controlled, Multicenter Study to Evaluate the Safety, Immunogenicity and Induction of Immunological Memory after Two or Three Doses of Novartis Meningococcal ACW... | ||||||||
Medical condition: Prevention of invasive disease caused by Neisseria Meningitidis serogroup A, C, W-135 and Y | ||||||||
|
||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||
Trial protocol: GB (Completed) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003842-34 | Sponsor Protocol Number: MK-5592-127 | Start Date: | |||||||||||
Sponsor Name: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | |||||||||||||
Full Title: A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole (POS, MK-5592) Intravenous and Powder for Oral Suspension Formul... | |||||||||||||
Medical condition: Invasive Fungal Infection | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) Outside EU/EEA BE (Ongoing) GR () | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002050-66 | Sponsor Protocol Number: PENTA 11 | Start Date: | ||||||
Sponsor Name: PENTA Foundation | ||||||||
Full Title: Treatment Interruption in Children with Chronic HIV-Infection: the TICCH Trial | ||||||||
Medical condition: Infected with Human Immunodeficiancy Virus - (HIV-Infection) | ||||||||
|
||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||
Trial protocol: IE (Ongoing) ES (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008435-29 | Sponsor Protocol Number: 3082B2-4433-WW | Start Date: | |||||||||||
Sponsor Name: Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company | |||||||||||||
Full Title: A Non-Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of ReFacto AF in Previously Treated Pediatric Subjects Less Than Twelve Years of Age With Severe Hemophilia... | |||||||||||||
Medical condition: Severe hemophilia A (FVIII:C | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) ES (Completed) IT (Completed) GR (Completed) CZ (Completed) SE (Completed) DK (Completed) FI (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003370-35 | Sponsor Protocol Number: MCT8-2019-2 | Start Date: | ||||||
Sponsor Name: Rare Thyroid Therapeutics International AB | ||||||||
Full Title: Tiratricol treatment of children with Monocarboxylate Transporter 8 deficiency: Triac Trial II | ||||||||
Medical condition: Monocarboxylate Transporter 8 (MCT8) deficiency | ||||||||
|
||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male | |||||||
Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) DE (Ongoing) CZ (Ongoing) NL (Ongoing) IT (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000122-10 | Sponsor Protocol Number: NS-065/NCNP-01-302 | Start Date: | |||||||||||
Sponsor Name: NS Pharma, Inc. | |||||||||||||
Full Title: A Phase 3, Multi-center, Open-label Extension Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys with Duchenne Muscular Dystrophy (DMD) | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy (DMD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: NL (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004187-35 | Sponsor Protocol Number: FACE-01 | Start Date: | |||||||||||
Sponsor Name: Falun Hospital | |||||||||||||
Full Title: The FACE (Facial nerve palsy And Cortisone Evaluation) study in children: a randomised double-blind, placebo-controlled, multicenter trial. | |||||||||||||
Medical condition: Facial Nerve Palsy (Bells Palsy) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004691-37 | Sponsor Protocol Number: | Start Date: | ||||||
Sponsor Name: St Vincents University Hospital | ||||||||
Full Title: Etanercept in Psoriasis and Psoriatic Arthritis: a single center, open-label study in 15 patients. | ||||||||
Medical condition: Psoriasis and Psoriatic Arthritis | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: IE (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001898-32 | Sponsor Protocol Number: V87_30 | Start Date: | |||||||||||
Sponsor Name: Seqirus UK Limited | |||||||||||||
Full Title: A Phase 2, Randomized, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Several Doses of Antigen and MF59 Adjuvant Content in a Monovalent H5N1 Pandemic Influenza Vacc... | |||||||||||||
Medical condition: Prophylaxis for Influenza virus | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Ongoing) Outside EU/EEA | |||||||||||||
Trial results: (No results available) |